{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-004942","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.863489+00:00","generated_at":"2026-06-12T10:33:31.113210+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioCryst Q2 ORLADEYO rev $81M (+24% YoY); on track for FY $320M; GAAP EPS ($0.40)","bullets":["ORLADEYO net revenue $81.0M in Q2 2023, up 24.2% YoY from $65.2M; total revenues $82.5M (+25.9% YoY).","GAAP net loss $75.3M ($0.40/share) vs $58.9M ($0.32/share) in Q2 2022; includes $29M one-time debt extinguishment fee.","Non-GAAP EPS ($0.24) after excluding the one-time fee; operating cash use $13.5M in Q2.","Reaffirmed FY 2023 ORLADEYO revenue guidance of >=$320M; peak revenue target $1B.","R&D day set for Nov 3, 2023 to introduce pipeline assets; BCX10013 trial enrollment in PNH expected by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-004942","json":"https://secwatch.observer/filing/0001171843-23-004942.json","markdown":"https://secwatch.observer/filing/0001171843-23-004942.md","text":"https://secwatch.observer/filing/0001171843-23-004942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184323004942/0001171843-23-004942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184323004942/f8k_080323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T10:33:31.113210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"334e74e22ebc2a1c1b618476c239958536568c8d","claim":"BIOCRYST PHARMACEUTICALS INC reported the second quarter ended June 30, 2023 results: revenue $82.5 million, net income Net loss for the second quarter of 2023 was $75.3 million, or $0.40 per share, EPS $0.40 per share. Guidance raised.","evidence_excerpt":"For the three months ended June 30, 2023, total revenues were $82.5 million, compared to $65.5 million in the second quarter of 2022 (+25.9 percent year-over-year (y-o-y)).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184323004942/0001171843-23-004942-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$82.5 million"},{"label":"Net income","value":"Net loss for the second quarter of 2023 was $75.3 million, or $0.40 per share"},{"label":"EPS","value":"$0.40 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}